94 related articles for article (PubMed ID: 32798277)
1. Piperlongumine inhibits head and neck squamous cell carcinoma proliferation by docking to Akt.
Lv F; Deng M; Bai J; Zou D; Wang J; Li H; Zhang Y; Ji X
Phytother Res; 2020 Dec; 34(12):3345-3358. PubMed ID: 32798277
[TBL] [Abstract][Full Text] [Related]
2. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
3. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.
Bharadwaj U; Eckols TK; Kolosov M; Kasembeli MM; Adam A; Torres D; Zhang X; Dobrolecki LE; Wei W; Lewis MT; Dave B; Chang JC; Landis MD; Creighton CJ; Mancini MA; Tweardy DJ
Oncogene; 2015 Mar; 34(11):1341-53. PubMed ID: 24681959
[TBL] [Abstract][Full Text] [Related]
4. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway.
Wang F; Mao Y; You Q; Hua D; Cai D
Int J Immunopathol Pharmacol; 2015 Sep; 28(3):362-73. PubMed ID: 26246196
[TBL] [Abstract][Full Text] [Related]
5. Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer.
Kumar S; Agnihotri N
Biomed Pharmacother; 2019 Jan; 109():1462-1477. PubMed ID: 30551398
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 inhibition.
Piska K; Koczurkiewicz P; Wnuk D; Karnas E; Bucki A; Wójcik-Pszczoła K; Jamrozik M; Michalik M; Kołaczkowski M; Pękala E
Chem Biol Interact; 2019 Feb; 300():40-48. PubMed ID: 30611789
[TBL] [Abstract][Full Text] [Related]
7. Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization.
Liu D; Qiu XY; Wu X; Hu DX; Li CY; Yu SB; Pan F; Chen XQ
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):165-172. PubMed ID: 29037814
[TBL] [Abstract][Full Text] [Related]
8. Osthole induces cell cycle arrest and apoptosis in head and neck squamous cell carcinoma by suppressing the PI3K/AKT signaling pathway.
Yang J; Zhu XJ; Jin MZ; Cao ZW; Ren YY; Gu ZW
Chem Biol Interact; 2020 Jan; 316():108934. PubMed ID: 31870840
[TBL] [Abstract][Full Text] [Related]
9. Blocking of stromal interaction molecule 1 expression influence cell proliferation and promote cell apoptosis in vitro and inhibit tumor growth in vivo in head and neck squamous cell carcinoma.
Li P; Bian XY; Chen Q; Yao XF; Wang XD; Zhang WC; Tao YJ; Jin R; Zhang L
PLoS One; 2017; 12(5):e0177484. PubMed ID: 28494008
[TBL] [Abstract][Full Text] [Related]
10. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells.
Shrivastava S; Kulkarni P; Thummuri D; Jeengar MK; Naidu VG; Alvala M; Redddy GB; Ramakrishna S
Apoptosis; 2014 Jul; 19(7):1148-64. PubMed ID: 24729100
[TBL] [Abstract][Full Text] [Related]
11. Piperlongumine-induced nuclear translocation of the FOXO3A transcription factor triggers BIM-mediated apoptosis in cancer cells.
Liu Z; Shi Z; Lin J; Zhao S; Hao M; Xu J; Li Y; Zhao Q; Tao L; Diao A
Biochem Pharmacol; 2019 May; 163():101-110. PubMed ID: 30753811
[TBL] [Abstract][Full Text] [Related]
12. Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP.
Chen Y; Liu JM; Xiong XX; Qiu XY; Pan F; Liu D; Lan SJ; Jin S; Yu SB; Chen XQ
Oncotarget; 2015 Mar; 6(8):6406-21. PubMed ID: 25788268
[TBL] [Abstract][Full Text] [Related]
13. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
[TBL] [Abstract][Full Text] [Related]
14. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
15. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.
Golovine K; Makhov P; Naito S; Raiyani H; Tomaszewski J; Mehrazin R; Tulin A; Kutikov A; Uzzo RG; Kolenko VM
Cancer Biol Ther; 2015; 16(5):743-9. PubMed ID: 25801713
[TBL] [Abstract][Full Text] [Related]
16. Piperlongumine decreases cell proliferation and the expression of cell cycle-associated proteins by inhibiting Akt pathway in human lung cancer cells.
Seok JS; Jeong CH; Petriello MC; Seo HG; Yoo H; Hong K; Han SG
Food Chem Toxicol; 2018 Jan; 111():9-18. PubMed ID: 29109039
[TBL] [Abstract][Full Text] [Related]
17. Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds.
Vishwakarma V; New J; Kumar D; Snyder V; Arnold L; Nissen E; Hu Q; Cheng N; Miller D; Thomas AR; Shnayder Y; Kakarala K; Tsue TT; Girod DA; Thomas SM
Sci Rep; 2018 Aug; 8(1):12163. PubMed ID: 30111862
[TBL] [Abstract][Full Text] [Related]
18. Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.
Han SS; Han S; Kamberos NL
Biochem Biophys Res Commun; 2014 Sep; 452(3):669-75. PubMed ID: 25193702
[TBL] [Abstract][Full Text] [Related]
19. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
